Full Text View
Tabular View
No Study Results Posted
Related Studies
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events (EXTEND)
This study has been terminated.
( Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety. )
Study NCT00206089   Information provided by AstraZeneca

First Received on September 13, 2005.   Last Updated on November 11, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Thromboembolism
Additional conditions recognized in this trial
Embolism
Hip Fractures
More general conditions related to this trial
Cardiovascular Diseases
Embolism and Thrombosis
Femoral Fractures
Fractures, Bone
Hip Injuries
Leg Injuries
Thrombosis
Vascular Diseases
Wounds and Injuries
Interventions listed in this trial
EXANTA
Additional drug interventions recognized in this trial
Enoxaparin
Melagatran
Ximelagatran
More general drug interventions related to this trial
Anticoagulants
Antithrombins
Cardiovascular Agents
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Serine Proteinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services